Alnylam Pharmaceuticals (ALNY) Revenue (2009 - 2026)

Alnylam Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• Quarterly Revenue rose 96.43% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 billion (up 82.57% YoY) and the FY2025 annual result came in at $3.7 billion, up 65.19% from the prior year.
• Revenue was $1.2 billion for Q1 2026 at Alnylam Pharmaceuticals, up from $1.1 billion in the prior quarter.
• Across five years, Revenue topped out at $1.2 billion in Q3 2025 and bottomed at $213.3 million in Q1 2022.
• A 5-year average of $587.9 million and a median of $500.9 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue soared 183.96% — and 2024, when it tumbled 33.26%.
• Alnylam Pharmaceuticals' Revenue stood at $335.0 million in 2022, then surged by 31.25% to $439.7 million in 2023, then soared by 34.9% to $593.2 million in 2024, then jumped by 84.95% to $1.1 billion in 2025, then advanced by 6.39% to $1.2 billion in 2026.
• Business Quant data shows ALNY's Revenue at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.2 billion in Q3 2025.